Northern Trust Corp Pro Qr Therapeutics N.V. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Northern Trust Corp holds 15,750 shares of PRQR stock, worth $43,942. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,750

Previous 15,932 1.14%

Holding current value

$43,942

Previous $26,000 7.69%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$1.64 - $2.24 $298 - $407	-182 Reduced 1.14%	15,750 $28,000
Q2 2024 Aug 14, 2024	SELL	$1.65 - $2.39 $2,455 - $3,556	-1,488 Reduced 8.54%	15,932 $26,000
Q2 2023 Aug 11, 2023	BUY	$1.62 - $2.32 $9,998 - $14,319	6,172 Added 54.87%	17,420 $28,000
Q1 2023 May 15, 2023	BUY	$1.99 - $3.66 $22,383 - $41,167	11,248 New	11,248 $23,000
Q1 2022 May 13, 2022	SELL	$0.9 - $8.39 $5,697 - $53,108	-6,330 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$6.58 - $8.44 $41,651 - $53,425	6,330 New	6,330 $51,000
Q3 2021 Nov 15, 2021	SELL	$5.16 - $8.47 $69,561 - $114,184	-13,481 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$5.75 - $7.59 $25,484 - $33,638	-4,432 Reduced 24.74%	13,481 $91,000
Q1 2021 May 12, 2021	BUY	$4.14 - $9.22 $74,159 - $165,157	17,913 New	17,913 $118,000
Q4 2019 Feb 14, 2020	SELL	$5.84 - $10.51 $226,253 - $407,178	-38,742 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$9.1 - $15.55 $39,539 - $67,564	4,345 Added 12.63%	38,742 $353,000
Q1 2019 May 13, 2019	SELL	$12.5 - $18.48 $97,500 - $144,144	-7,800 Reduced 18.48%	34,397 $477,000
Q4 2018 Feb 12, 2019	BUY	$15.25 - $22.4 $643,504 - $945,212	42,197 New	42,197 $666,000

Others Institutions Holding PRQR

# of Institutions

Shares Held

17.4M

Call Options Held

37.7K

Put Options Held

21.3K

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $199M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Pro Qr Therapeutics N.V. Transaction History